Medical Sciences Correction for “New intranasal and injectable gene therapy for healthy life extension,” by Dabbu Kumar Jaijyan, Anca Selariu, Ruth Cruz-Cosme, Mingming Tong, Shaomin Yang, Alketa Stefa, David Kekich, Junichi Sadoshima, Utz Herbig, Qiyi Tang, George Church, Elizabeth L. Parrish, and Hua Zhu, which published May 10, 2022; 10.1073/pnas.2121499119 (Proc. Natl. Acad. Sci. U.S.A. 119, e2121499119).
The authors note, “We are updating our competing interest disclosure about several items to provide further transparency. Reviewer William Andrews currently serves on the Scientific Advisory Board of BioViva USA, Inc. However, Dr. Andrews did not become associated with BioViva until after the article was accepted for publication and he is solely responsible for having initiated the relationship. Anca Selariu has served as Chief Scientific Officer for BioViva in a volunteer capacity but has never received compensation or equity for this role and has never been an employee of BioViva. Hua Zhu is a Principal Investigator for BioViva and his Rutgers University laboratory receives funding from BioViva for his research but has never been an employee of BioViva.
"George Church’s research contributions were conducted as part of his role as a consultant for BioViva USA, Inc. and not as part of a project administered through Harvard Medical School. We also note that David Kekich died on September 9, 2021.”
The article has been updated with a revised competing interest statement and a note that David Kekich is deceased.